Related Experiment Video
Updated: Dec 31, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
The Aspirin Primary Prevention Conundrum
Miri Schamroth Pravda1,2, Nili Schamroth Pravda3,2, Yitzhak Beigel4,2
1Department of Internal Medicine A, Meir Medical Center, Kfar Saba, Israel.
Insights
This review examines aspirin's role in preventing cardiovascular disease. It analyzes current evidence for aspirin in primary prevention, especially for those with moderate risk, diabetes, or in older populations.
Area of Science:
- Cardiology
- Preventive Medicine
- Pharmacology
Background:
- Aspirin has a long history in cardiovascular disease prevention.
- Current guidelines and recent evidence are re-examined.
- Focus on primary prevention strategies.
Purpose of the Study:
- To re-evaluate aspirin's efficacy in primary cardiovascular disease prevention.
- To analyze recent evidence in specific patient groups.
- To inform clinical practice regarding aspirin use.
Main Methods:
- Literature review of historical and recent studies.
- Analysis of clinical trial data.
- Synthesis of evidence for different risk populations.
Main Results:
- Evidence synthesis on aspirin's benefits and risks in primary prevention.
- Evaluation of aspirin use in moderate cardiovascular risk individuals.
- Assessment of aspirin's role in diabetes mellitus and elderly populations.
Conclusions:
- Aspirin's role in primary prevention requires careful consideration of individual risk.
- Recent evidence may modify recommendations for specific populations.
- Further research may refine optimal aspirin use strategies.
Background:
In this review, the authors re-examine the role of aspirin in the primary prevention of cardiovascular disease. They discuss the history of the use of aspirin in primary prevention, the current guidelines, and the recent evidence surrounding aspirin use as primary prevention in special populations such as those with moderate cardiovascular risk, diabetes mellitus, and the elderly.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Preventive Healthcare Services
Coronary Artery Disease IV: Preventive Measures

